Literature DB >> 16533744

Myelodysplastic syndrome.

Shinji Nakao1, H Joachim Deeg, Takayuki Ishikawa, Judith Marsh, Alan List, Masao Tomonaga.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16533744     DOI： 10.1532/IJH97.05139

Source DB:  PubMed          Journal:  Int J Hematol        ISSN： 0925-5710            Impact factor:   2.490


× No keyword cloud information.
  25 in total

1.  Autoimmune myelodysplasias.

Authors:  P A Miescher; H Favre; P Beris
Journal:  Semin Hematol       Date:  1991-10       Impact factor: 3.851

2.  Thalidomide for the treatment of patients with myelodysplastic syndromes.

Authors:  C Strupp; U Germing; M Aivado; E Misgeld; R Haas; N Gattermann
Journal:  Leukemia       Date:  2002-01       Impact factor: 11.528

3.  Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow.

Authors:  A Jonásova; R Neuwirtová; J Cermák; V Vozobulová; K Mociková; M Sisková; I Hochová
Journal:  Br J Haematol       Date:  1998-02       Impact factor: 6.998

4.  Paroxysmal nocturnal hemoglobinuria cells in patients with bone marrow failure syndromes.

Authors:  D E Dunn; P Tanawattanacharoen; P Boccuni; S Nagakura; S W Green; M R Kirby; M S Kumar; S Rosenfeld; N S Young
Journal:  Ann Intern Med       Date:  1999-09-21       Impact factor: 25.391

5.  Antithymocyte globulin for patients with myelodysplastic syndrome.

Authors:  J J Molldrem; M Caples; D Mavroudis; M Plante; N S Young; A J Barrett
Journal:  Br J Haematol       Date:  1997-12       Impact factor: 6.998

Review 6.  The role of angiogenesis in the biology and therapy of myelodysplastic syndromes.

Authors:  Alvaro Aguayo
Journal:  Curr Hematol Rep       Date:  2004-05

Review 7.  Autoimmune phenomena in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia.

Authors:  Muhammad Wasif Saif; Jon L Hopkins; Steven D Gore
Journal:  Leuk Lymphoma       Date:  2002-11

8.  HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome.

Authors:  Yogen Saunthararajah; Ryotaro Nakamura; Jun-Mo Nam; Jamie Robyn; Fausto Loberiza; Jaroslaw P Maciejewski; Toni Simonis; Jeffrey Molldrem; Neal S Young; A John Barrett
Journal:  Blood       Date:  2002-09-01       Impact factor: 22.113

9.  A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndrome.

Authors:  Yogen Saunthararajah; Ryotaro Nakamura; Robert Wesley; Qiong J Wang; A John Barrett
Journal:  Blood       Date:  2003-06-26       Impact factor: 22.113

10.  Clinical significance of a minor population of paroxysmal nocturnal hemoglobinuria-type cells in bone marrow failure syndrome.

Authors:  Hongbo Wang; Tatsuya Chuhjo; Shizuka Yasue; Mitsuhiro Omine; Shinji Nakao
Journal:  Blood       Date:  2002-08-08       Impact factor: 22.113
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.